U.K. pharmaceutical company GlaxoSmithKline said its experimental cancer vaccine MAGE-A3 has failed to achieve an important trial milestone, dealing a blow to one of the company's more promising drugs in development.
LONDON—U.K. pharmaceutical company GlaxoSmithKline PLC said Thursday that its experimental cancer vaccine MAGE-A3 has failed to achieve an important trial milestone, dealing a blow to one of the company’s more promising drugs in development. Glaxo said the drug didn’t meet one of its primary goals in a late-stage trial in patients with melanoma
0 comments:
Post a Comment